---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-017226"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2026-01-21T23:59:59+00:00"
generated_at: "2026-05-16T09:21:50.053205+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# enGene expands debt facility with Hercules to $125M, $25M funded to refinance existing debt

## Summary
- Up to $125M debt facility from Hercules Capital; $25M funded at closing to refinance existing debt.
- Three additional tranches up to $75M available upon achieving clinical, regulatory, and commercial milestones; final $25M at Hercules' discretion.
- Maturity date January 1, 2030; proceeds support detalimogene BLA filing in H2 2026 and potential launch in 2027.
- Non-dilutive capital strengthens balance sheet for planned BLA in BCG-unresponsive NMIBC with carcinoma in situ.

## SEC filing metadata
- accession: 0001193125-26-017226
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2026-01-21T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000119312526017226/0001193125-26-017226-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000119312526017226/engn-20260120.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-017226
- JSON: https://secwatch.observer/filing/0001193125-26-017226.json
- Plain text: https://secwatch.observer/filing/0001193125-26-017226.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.